文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

T细胞去除策略对特发性再生障碍性贫血造血干细胞移植结局的影响:欧洲血液与骨髓移植严重再生障碍性贫血工作组代表研究

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.
PubMed 文献 · Am J Hematol · 2018-11-25

该研究回顾性分析了2000至2013年间1837例接受同胞全合或无关全合造血干细胞移植的严重再生障碍性贫血成人和儿童患者,按预处理是否含抗胸腺细胞球蛋白、阿仑单抗或无血清治疗分组。结果显示含血清治疗降低慢性移植物抗宿主病并带来生存优势,阿仑单抗较抗胸腺细胞球蛋白降低急性和慢性移植物抗宿主病风险。

要点

  • 含血清治疗(抗胸腺细胞球蛋白或阿仑单抗)较无血清治疗降低慢性移植物抗宿主病风险。
  • 阿仑单抗较抗胸腺细胞球蛋白降低急性移植物抗宿主病风险(P=0.012)。
  • 阿仑单抗较抗胸腺细胞球蛋白降低慢性移植物抗宿主病风险(HR 0.58;95%CI 0.35-0.94;P=0.027)。

核心结论

  • 在严重再生障碍性贫血的同胞全合和无关全合造血干细胞移植中,预处理加入血清治疗可降低慢性移植物抗宿主病并提供生存优势。
  • 阿仑单抗较抗胸腺细胞球蛋白降低急性和慢性移植物抗宿主病风险,提示阿仑单抗可能是严重再生障碍性贫血同胞全合和无关全合移植的血清治疗选择。

研究设计与样本

  • 回顾性分析2000至2013年间1837例接受同胞全合或无关全合造血干细胞移植的严重再生障碍性贫血成人和儿童患者。
  • 按预处理是否含抗胸腺细胞球蛋白(n=1283)、阿仑单抗(n=261)或无血清治疗(n=293)分组。

主要发现

  • 与无血清治疗相比,抗胸腺细胞球蛋白(P=0.021)和阿仑单抗(P=0.003)显著降低慢性移植物抗宿主病风险。
  • 阿仑单抗较抗胸腺细胞球蛋白(P=0.012)和无血清治疗(P<0.001)显著降低急性移植物抗宿主病风险。
  • 多因素分析显示,与抗胸腺细胞球蛋白相比,阿仑单抗与较低的急性移植物抗宿主病风险相关(OR 0.262;95%CI 0.14-0.47;P<0.001)。
  • 多因素分析显示,与抗胸腺细胞球蛋白相比,阿仑单抗与较低的慢性移植物抗宿主病风险相关(HR 0.58;95%CI 0.35-0.94;P=0.027)。
  • 抗胸腺细胞球蛋白(P=0.010)和阿仑单抗(P=0.025)组的总生存显著优于无血清治疗组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti-thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14-0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35-0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Samarasinghe S, Clesham K, Iacobelli S, et al. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. Am J Hematol. 2018. PMID: 30328134. doi:10.1002/ajh.25314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。